logo
How 5 years of COVID-19 has prepared Toronto to face potential crises in the future

How 5 years of COVID-19 has prepared Toronto to face potential crises in the future

CBC14-03-2025
Five years on, Toronto-area doctors and public health officials are looking back at what they've learned since the start of the COVID-19 pandemic — and most agree the early experience will prove useful if the city faces another infectious disease crisis.
"The biggest thing was fear and uncertainty," Dr. Justin Hall told CBC Toronto. Hall is chief of emergency medicine at Sunnybrook Health Sciences Centre, where Canada's first case of COVID-19 was identified on Jan. 25, 2020.
"Our staff responded extremely well to not knowing what was going to happen and every day looked a little bit different," he said.
March 11 marked the fifth anniversary of the World Health Organization's declaration of COVID-19 as a pandemic. In the days that followed that announcement, the provincial government declared a state of emergency, with the City of Toronto following suit soon after.
While most will remember those unprecedented times for lockdowns, mask mandates and vaccine rollouts, Hall said there were many other useful lessons learned about minimizing the spread of disease.
"We were able to have a lot of innovation during this time," he said. "That's one thing that I hope will continue to last and that we won't forget because of the pandemic."
One example of that innovation is the virtual emergency department, which Hall says is still operating and was created through a partnership between Sunnybrook, University Hospital Network and Toronto Unity Health.
According to Sunnybrook's website, the virtual emergency department offers same-day online appointments with emergency department physicians, minimizing the need for people to come to the hospital in person. While its initial purpose was to help address the pandemic, the service also aims to help under-served populations and reduce emergency room wait times.
Communication key, health experts say
Dr. Na-Koshie Lamptey, Toronto's acting medical officer of health, told CBC Toronto the city is more prepared to handle an infectious disease crisis now than it was before COVID-19.
"Communication was so key to an effective response," she said. "The coordination and networks that were built up … the way the hospitals, public health, primary care and social services settings really were all sharing information in new ways. I think that is going to help us coordinate better if there should be another challenge."
That "Team Toronto" coordination has already proven useful to help tackle issues of income, food security and transportation, Lamptey said.
She says she's hopeful that those networks are maintained to help better position the city and Toronto Public Health in the event of a potential new pandemic.
"We really felt at the time that we were building the ship as we sailed it," Dr. Samira Mubareka told CBC Toronto of the early days of the pandemic.
Mubareka, an infectious disease specialist and medical microbiologist at Sunnybrook, says now there are "fortunately" less restrictions on those who can study and work with "high consequence coronaviruses."
"When SARS-coronavirus-2 landed here in Canada, you could count on one hand the number of individuals who were familiar with coronaviruses," she said.
This level of preparedness needs to be maintained, especially with regard to vaccine distribution, she said
"Understanding the biology is key for vaccine development," Mubareka said. "But unless you have the right pieces for coordinating and implementing and rolling out vaccines, which includes everything from logistics to communication, social sciences, public health, all of those things, they all have to work together in a coordinated fashion."
Any reflections on the first five years of the pandemic need to include looking at the wide-ranging impacts of COVID-19, Lamptey said.
"It really is a chance to reflect on the lives that were lost, to honour the workers who contributed to the response, to protect the public," she said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

McGill University team develops AI that can detect infection before symptoms appear
McGill University team develops AI that can detect infection before symptoms appear

Winnipeg Free Press

time5 minutes ago

  • Winnipeg Free Press

McGill University team develops AI that can detect infection before symptoms appear

MONTRÉAL – Researchers at McGill University say they developed an artificial intelligence platform that can predict when someone is about to come down with a respiratory tract infection before they start to feel sick. In what researchers are calling a 'world first,' the study involved participants who wore a ring, a watch and a T-shirt, all of which were equipped with censors that recorded their biometric data. By analyzing the data, researchers were able to accurately predict acute systemic inflammation — an early sign of a respiratory infection such as COVID-19. Published in The Lancet Digital Health, the study says the AI platform can one day help doctors address health problems much earlier than they normally would, particularly in patients who are fragile and for whom a new infection could have serious consequences. It could also potentially reduce costs for the health-care system by preventing complications and hospitalizations. 'We were very interested to see if physiological data measured using wearable sensors … could be used to train an artificial intelligence system capable of detecting an infection or disease resulting from inflammation,' explained the study's lead author, Prof. Dennis Jensen of McGill University's department of kinesiology and physical education. 'We wondered if we could detect early changes in physiology and, from there, predict that someone is about to get sick.' Jense says the AI model his team created is the first in the world to use physiological measures — including heart rate, heart rate variability, body temperature, respiratory rate, blood pressure — rather than symptoms, to detect a problem. Acute systemic inflammation is a natural defence mechanism of the body that usually resolves on its own, but it can cause serious health problems, especially in populations with pre-existing conditions. 'The whole idea is kind of like an iceberg,' Jensen said. 'Kind of when the ice cracks the surface, that's like when you're symptomatic, and then it's too late to really do much to treat it.' During the study, McGill researchers administered a weakened flu vaccine to 55 healthy adults to simulate infection in their bodies. The subjects were monitored seven days before inoculation and five days after. Participants wore a smart ring, smart watch, and a smart T-shirt simultaneously throughout the study. As well, researchers collected biomarkers of systemic inflammation using blood samples, PCR tests to detect the presence of respiratory pathogens, and a mobile app to collect symptoms reported by participants. In total, more than two billion data points were collected to train machine learning algorithms. Ten different AI models were developed, but the researchers chose the model that used the least amount of data for the remainder of the project. The chosen model correctly detected nearly 90 per cent of actual positive cases and was deemed more practical for daily monitoring. On their own, Jensen said, none of the data collected from the ring, watch, or T-shirt alone is sensitive enough to detect how the body is responding. 'An increase in heart rate alone may only correspond to two beats per minute, which is not really clinically relevant,' he explained. 'The decrease in heart rate variability can be very modest. The increase in temperature can be very modest. So the idea was that by looking at … several different measurements, we would be able to identify subtle changes in physiology.' Wednesdays What's next in arts, life and pop culture. The algorithms also successfully detected systemic inflammation in four participants infected with COVID-19 during the study. In each case, the algorithms flagged the immune response up to 72 hours before symptoms appeared or infection was confirmed by PCR testing. Ultimately, the researchers hope to develop a system that will inform patients of possible inflammation so they can contact their health-care provider. 'In medicine, we say that you have to give the right treatment to the right person at the right time,' Jensen said. By expanding the therapeutic window in which doctors can intervene, he added, they could save lives and achieve significant savings by avoiding hospitalizations and enabling home management of chronic conditions or even aging. 'In a way, we hope to revolutionize personalized medicine.' This report by The Canadian Press was first published July 30, 2025.

FDA vaccine chief leaving agency after less than 3 months
FDA vaccine chief leaving agency after less than 3 months

Winnipeg Free Press

time35 minutes ago

  • Winnipeg Free Press

FDA vaccine chief leaving agency after less than 3 months

WASHINGTON (AP) — The Food and Drug Administration's polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of biotech companies, patient groups and conservative allies of President Donald Trump. Dr. Vinay Prasad 'did not want to be a distraction' and was stepping down from his role as the FDA's top vaccine regulator 'to spend more time with his family,' a spokesperson for the Department of Health and Human Services said in a statement late Tuesday. Two people familiar with the situation told The Associated Press that Prasad was ousted following several recent controversies. The people spoke on condition of anonymity to discuss internal personnel matters. Prasad joined the FDA in May after years as an academic researcher at the University of California San Francisco, where he frequently criticized the FDA's approach to drug approvals and COVID-19 vaccines. His contrarian approach appeared to match FDA Commissioner Marty Makary, who repeatedly praised Prasad's work and intellect. But in recent weeks Prasad became a target of conservative activists, including Laura Loomer, who flagged Prasad's past statements criticizing Trump and praising liberal independent Senator Bernie Sanders. 'How did this Trump-hating Bernie Bro get into the Trump admin???' Loomer posted on X last week. Prasad also attracted scrutiny for his handling of a recent safety issue surrounding the only approved gene therapy for Duchenne's muscular dystrophy. Under his direction, shipments of the therapy were briefly halted after a series of patient deaths, then resumed late Monday following vocal pushback from families of boys with the fatal muscle-wasting disorder. Prasad has long been skeptical of the therapy and other muscular dystrophy drugs sold by the drugmaker, Sarepta Therapeutics. As an academic, Prasad gained prominence by attacking the FDA for being too lenient in its standards for approving cancer drugs and other new therapies. That approach is at odds with Trump's Republican supporters, who generally favor speedier approvals and unfettered access to experimental treatments. During Trump's first term he signed the ' Right to Try ' law, a largely symbolic piece of legislation that won popular support from conservatives seeking to give dying patients expanded access to unproven drugs. Prasad's decision to pause Sarepta's therapy was criticized last week by a columnist and the editorial board of The Wall Street Journal. Wednesdays What's next in arts, life and pop culture. Separately, Prasad's division issued rejection letters this month to three small biotech firms seeking approval for new gene therapies. Prasad's predecessor in the role, Dr. Peter Marks, oversaw a steep rise in approvals for new gene therapies, which aim to treat or prevent disease by replacing or modifying a portion of patients' genetic code. Prasad has been an outspoken critic of Marks' leadership at FDA. which included overseeing the approval of the first COVID vaccines and therapies. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Mountain Valley MD Provides Business Update, Advances Commercialization Strategies
Mountain Valley MD Provides Business Update, Advances Commercialization Strategies

National Post

time2 hours ago

  • National Post

Mountain Valley MD Provides Business Update, Advances Commercialization Strategies

Article content TORONTO — Mountain Valley MD Holdings Inc. (the 'Company' or 'MVMD') (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a business update on its commercialization progress across its three core areas of focus: Article content Nutraceuticals – Innovations through the Company's Quicksome™ technology, designed to improve the administration and efficacy of nutraceutical health and wellness products; Agriculture – The Company's licensed Agrarius agricultural plant signaling technology, designed to organically drive increased crop yields, reduce fertilizer and pesticide usage where desired, and enhance plant health; and Husbandry Animals/Aquatic Species – The application of solubilized drug formulations through the Company's Quicksol™ technology, designed to positively impact the health of husbandry animals and aquatic species. Article content 'In recent months, we have focused on measured execution across all business lines,' said Dennis Hancock, President & CEO of Mountain Valley MD. 'We continue to advance the commercial foundations needed to bring our technologies to market at scale, supported by progress in field trials and product launches.' Article content NUTRACEUTICALS Article content Quicksome™ Technology, Commercialization, and Business Development Progress Article content MVMD's patented liposomal Quicksome™ technology uses proprietary formulations and stabilizing agents to encapsulate active ingredients with the goal of optimizing molecule delivery in sublingual nutraceutical applications. The Company's Quicksome™ technology is currently focused on delivering molecules where enhanced efficacy, precise dosing, reduced variability, and dose sparing are valued. Article content 'Our Quicksome™ technology has proven adaptable across multiple product formulations,' Mr. Hancock noted. 'We believe the platform's dose-sparing benefits and demonstrated efficacy versus orally consumed competitors will continue to attract new partners and product opportunities in this scaled commercialization phase.' Article content MVMD continues to advance its nutraceutical strategy through its exclusive manufacturing and licensing arrangement with a U.S.-based GMP production partner (the 'Lead Manufacturer'). The Lead Manufacturer has GMP and OTC drug manufacturing capabilities and has installed proprietary equipment for producing MVMD's Quicksome™ sublingual and dermal formulations. Article content The Lead Manufacturer works closely with the Company to complete product and production elements necessary to support it's obligations under MVMD's license agreement with Circadian Wellness Corp. ('Circadian'), an MVMD licensee, as well as MVMD's proprietary 'Mountains Of…' product line and other business development initiatives. During the first half of the 2025 calendar year, MVMD and its Lead Manufacturer supported the scaled-up production and market launch of Circadian's 'Eons Dialed,' a sublingual product for anxiety support. Circadian's product line, which includes 'Eons Deeper Sleep' and 'Eons Dialed,' is manufactured by the Lead Manufacturer and incorporates Quicksome™ technology. Circadian reported positive consumer reception to its Quicksome™-based products, including USD $193,000 in sales during April to June 2025, a notable increase from prior periods. Article content In parallel, MVMD is engaged in business development initiatives with the Lead Manufacturer to secure additional nutraceutical licensing partnerships. A key project the Company has been advancing involves a U.S.-based multi-level marketing client (the 'MLM Client') for a novel fenugreek glycosides testosterone formulation. The Lead Manufacturer has secured distribution rights for a standardized ingredient with clinically demonstrated effects on total and biologically active free testosterone. The product has been successfully integrated into a Quicksome™ quick-dissolve tablet, and has supported testosterone levels in male subjects through documented trials. Human testosterone levels are well documented to positively impact muscle mass, strength, energy, vitality, libido, and spermatogenesis. The MLM Client has completed multiple rounds of product feedback regarding dissolution and flavor, with commercial terms anticipated in calendar 2025. A white-label version is also planned for manufacturing for broader distribution in the current calendar quarter. Article content MVMD has also completed development of additional formulations for energy, lean metabolism, focus, stress, and anxiety support. These are available for manufacturing through the Lead Manufacturer and are intended to support MVMD's branding and additional business development efforts through the remainder of calendar 2025. The Company's nutraceutical pipeline also includes active development projects for hematological health, nutritional support, hydration and performance, joint health, and pain management. Article content The Company's 'Mountains Of…' proprietary brand has secured U.S. trademark protection for multiple product categories (Sleep, Energy, Relief, Libido, Lean) to support GMP product sample development and business development activities. Distribution partners may elect to market MVMD's 'Mountains Of…' products or produce proprietary versions with their own branding. Article content AGRICULTURE Article content 'We believe the results of our collaboration with agronomists and agricultural partners throughout Latin America continue to validate the numerous Agrarius benefits across major crop types in diverse real-world conditions,' Mr. Hancock stated. 'We view being intentional with our data-driven approach as being the foundation for long-term adoption and meaningful commercial growth.' Article content MVMD has been working to advance commercialization in its agricultural division, which is focused on the licensed distribution of the Agrarius plant signaling technology. Under its exclusive license agreement with Agrarius Corp. ('AC'), MVMD holds the exclusive rights to sell the Agrarius product throughout North America, Mexico, Central America, South America, and the Caribbean (the 'Exclusive Territory'). While MVMD does not manufacture the product, it facilitates regional regulatory approvals, product trials, import logistics, business development, and commercial distribution across the Exclusive Territory. Article content The Agrarius product is mixed either with water or with other agricultural products, such as fertilizers, pesticides, or herbicides, at the point of application and then applied via sprayer to agricultural crops at ideal times during a plant's lifecycle. Agrarius has been tested across numerous major agricultural crops and has demonstrated its ability to naturally increase crop yields with results varying depending on crop type, reduce fertilizer usage, and increase general resilience to pests and climate change forces such as drought. Article content The Company is entering what it characterizes as a new phase of its validation and commercialization strategy in the Exclusive Territory, in particular in Latin America (LATAM), following the completion of an initial cycle of professional field trials in Brazil across key crops – including corn, sugarcane, soybeans, potatoes, and citrus – alongside an extensive evaluation program with soybean farmers in high-productivity environments. Article content The Company's agronomists have been working closely with certified third-party agricultural testing partners, academic institutions, and farmers to conduct product trials, including extensive metabolic and physiological analysis studies for Agrarius-treated crops. The Company believes that recent trial results continue to validate the efficacy of the Agrarius product and will support its planned product adoption and broad commercialization strategy. A sample of recently achieved key trial outcomes, includes: Article content Corn: In a study conducted by UNESP (Universidade Estadual Paulista), Agrarius application led to improved physiological conditions, higher chlorophyll concentrations, and increased root systems. This resulted in a yield increase of 14.8% in the Dourados region and 11.2% in the Santa Cruz area in Brazil. Sugarcane: Trials conducted by Agroquatro A.S, a company in Brazil that promotes and markets plant nutrition products, demonstrated a significant yield improvement of 8 to 12 tons per hectare (approximately 10%), a 15% increase in sugar yield, and a 47% reduction in damage caused by pests. Soybeans: Across 14 validation trials with farmers in Brazil, the application of Agrarius resulted in an average yield increase of 6.34 sacs per hectare. Notably, one high-performance producer participating in the Brazilian Soybean Strategic Committee ('CESB') Competition achieved a 15.61% productivity gain, yielding 117.93 bags/ha with Agrarius versus 102 bags/ha without. Potatoes: A field test harvested in June 2025 showed a productivity increase of 18.49%, with the Agrarius-treated area yielding 51,250 Kg/Ha compared to the control area's 43,250 Kg/Ha. Citrus: Preliminary results from trials on mature Hamlin orange trees showed a productivity increase of 5.29%. Satellite data analysis from the Company's contracted satellite monitoring subscription, OneSoil, visually shows a potential productivity improvement of up to 15% that will be assessed physically in the final harvest. This is consistent with previous trials the company conducted on citrus in Costa Rica. Article content 'The results we are seeing from Agrarius trials in Latin America confirm to us its performance in diverse real-world conditions,' continued Mr. Hancock. 'Completing effective Agrarius trials helps build the confidence needed for larger agricultural operators to continue evaluating the impact of successfully integrating Agrarius more broadly into their operations.' Article content The Company has commenced additional professionally managed testing protocols on cotton, coffee, and citrus, along with a second cycle for sugarcane and broad farmer-led validations for wheat and barley that would mirror what was recently accomplished with soybean trialing. Article content In Colombia, MVMD has commenced a grass productivity program in partnership with FEDEGAN, the national cattle growers' federation, which supports agricultural farms covering approximately 43 million hectares of cattle pastures. The study spans seven regions and targets productivity, nutritional content, and growth cycles on different grass types when Agrarius is applied versus control groups. The trial is being managed in coordination with local agronomists and technical directors, and is expected to run through calendar 2026, with preliminary results anticipated in the 2025 calendar year. The initial trialing and business development efforts the Company has been conducting with its third-party research partners and initial agricultural prospects has provided clarity to management that it is more likely that large-scale clients will require several cycles of crop trialing experience with Agrarius before more broadly adopting the Agrarius product in a meaningful scale in their operation. Article content Operationally, the Company completed its first trial import and clearance of its product samples into Brazil through its Panamanian logistics partner located in the Pana Park duty-free zone. This process established the customs and fiscal structure necessary for potential future larger-scale commercial shipments into Brazil. Article content MVMD continues to manage regulatory filings across the Exclusive Territory and has secured registration in Canada, Brazil, Colombia, Panama, Bolivia, Peru and most of the US states. Additional filings are in process for Mexico, Costa Rica, and Uruguay. To protect the Agrarius brand, MVMD has filed trademark applications in thirteen key jurisdictions across LATAM. Article content The Performance Guarantee Program ('PGP') remains a central element of MVMD's go-to-market strategy. Under the program, participating clients only pay for product after achieving defined performance thresholds. The Company believes this model has effectively reduced hesitation in early adoption for testing purposes, while generating valuable field data. MVMD and AC share the risk of performance, with AC deferring payment from MVMD until the PGP performance obligations are met. The Company believes this structure will drive revenue conversion as it scales into more significant field applications across the Exclusive Territory and is working with AC to understand how it will manage PGP opportunities in LATAM against current business development activity. Article content 'The combination of consistent trial results, expanding regulatory approvals, and the Performance Guarantee Program is intended to position Agrarius for scaled adoption,' Mr. Hancock said. 'We view these as the key steps that will move us from testing into commercial use.' Article content MVMD has applied its Quicksol™ solubilization technology to Ivermectin to create its Soluvec™ 1% formulation, which the Company designed to provide a safer and more effective solution for broad administration across husbandry animals and aquatic species. The Soluvec™ 1% formulation has been documented to have a nine-month stability at both room and refrigerated temperatures through a third-party Contract Manufacturing Operator in the United States. The Company's primary commercialization approach is to license this technology to third parties. Article content MVMD previously entered into a license agreement for Soluvec™ 1% animal husbandry applications in Bangladesh with a privately held Ontario corporation holding exclusive rights to manufacture and distribute Soluvec™ 1% products in injectable and feed coating formats in Bangladesh. Under this agreement, MVMD earns a royalty on net sales in the region. Article content As of July 2025, the Licensee has produced approximately 200 tonnes of Soluvec™ 1% coated fish feed distributed through five local distributors. Royalty revenues have been below management's expectations, impacted in part by damage to the farmed fishing industry from Cyclone Remal in 2024. MVMD has communicated performance concerns to it's licensee and will monitor sales over the coming quarters. Article content Global interest in Soluvec™ remains positive in management's view. In an effort to grow future Soluvec™ 1% formulation royalties, MVMD intends to accelerate broader commercialization efforts across Latin America and other emerging markets in future quarters. The Company has filed for patent protection in 12 additional markets outside of the United States, including Canada, China, India, Mexico, Sri Lanka, Thailand, Philippines, Malaysia, Brazil, Peru, Argentina, and Chile. Article content The Company's published peer-reviewed study data in the journal Therapeutic Delivery supports the improved bioavailability, efficacy, and potential cost savings of Soluvec™ for both animals and potentially human health applications. Article content 'Soluvec™ continues to demonstrate to us its measurable advantages in stability, bioavailability, and application,' said Mr. Hancock. 'Our priority is to support the existing licensee in Bangladesh while advancing expansion into additional markets where our patents support strategic capital deployment.' Article content ABOUT MOUNTAIN VALLEY MD HOLDINGS INC. Article content Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations: Article content Consistent with its vision towards 'More Life', MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD's work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage. Article content MVMD's patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy. Article content MVMD's patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally. Article content MVMD's licensed Agrarius™ agricultural plant signaling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change. Article content SOURCE: Mountain Valley MD Holdings Inc. Article content Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as 'anticipate', 'plan', 'estimate', 'expect', 'may', 'will', 'intend', 'should', and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Article content The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. Article content The Company is making forward-looking statements, including but not limited to: the continued interest of third parties in the Quicksome™ technology and the timing thereof; that recent Agrarius trial results will support the planned production adoption and broad commercialization strategy; future testing/trials, including timing, locations and products (of Agrarius); the PGP and the results and impact thereof; and the monitoring of licensee operations in Bangladesh and the timing thereof. Article content The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation. Article content Article content Article content Article content Article content Contacts Article content For further information: Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store